

Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis

Davor Vukadinović¹, MD, Lucas Lauder¹, MD, David E. Kandzari², MD, Deepak L. Bhatt³, MD, MPH, MBA, Ajay Kirtane⁴, MD, SM, Elazer R. Edelman^{5,6}, MD, PhD, Roland E. Schmieder⁷, MD, Michel Azizi^{8,9} MD, PhD, Michael Böhm¹, MD, Felix Mahfoud^{1,5}, MD, MA

¹ Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg, Germany.

² Piedmont Heart Institute, Atlanta, GA, USA.

³ Mount Sinai Fuster Heart Hospital, Icahn School of Medicine, New York, NY, USA

⁴ Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA.

⁵ IMES, Massachusetts Institute of Technology, Cambridge, MA, USA.

⁶ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

⁷ Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen/Nuremberg, Germany.

⁸ Université Paris Cité, Paris, France.

⁹ Hypertension Department, AP-HP, Hôpital, Georges-Pompidou, Paris, France.

Short title: Meta-analysis of renal denervation in hypertension

Total word count (Title Page, Abstract, Text, References, Tables and Figure Legends): 7,265.

Corresponding author:

Davor Vukadinović, MD

Saarland University Hospital

Klinik für Innere Medizin III

Kardiologie, Angiologie und Internistische Intensivmedizin

Kirrberger Strasse 100, D-66421 Homburg, Germany

Email: Davor.Vukadinovic@uks.eu

Tel: +49 06841/ 16-15500

Fax: +49 06841/ 16-15995

1 **Abstract: 256 words**

2 **Background:** Several sham-controlled trials have investigated the efficacy and safety of
3 catheter-based renal denervation (RDN) with mixed outcomes.

4 **Aim:** To perform a comprehensive meta-analysis of all randomized, sham-controlled trials
5 investigating RDN with first- and second-generation devices in hypertension.

6 **Methods:** We searched MEDLINE and Cochrane Library for eligible trials. Outcomes included
7 both efficacy (24-hour and office systolic [SBP] and diastolic blood pressure [DBP]) and safety
8 (all-cause death, vascular complication, renal artery stenosis >70%, hypertensive crisis) of RDN.
9 We performed a study-level, pairwise, random-effects meta-analysis of the summary data.

10 **Results:** Ten trials comprising 2,478 patients with hypertension while being either off- or on-
11 treatment were included. Compared with sham, RDN reduced 24-hour and office systolic BP by
12 4.4 mmHg (95%CI -6.1, -2.7, $p<0.00001$) and 6.6 mmHg (95%CI -9.7, -3.6, $p<0.0001$),
13 respectively. The 24-hour and office diastolic BP paralleled these findings (-2.6 mmHg, 95%CI -
14 3.6, -1.5, $p<0.00001$; -3.5 mmHg, 95%CI -5.4, -1.6, $p=0.0003$). There was no difference in 24-
15 hour and office SBP reduction between trials with and without concomitant antihypertensive
16 medication (p for interaction 0.62 and 0.73, respectively). There was no relevant difference
17 concerning vascular complications (OR 1.69, 95%CI 0.57-5.0, $p=0.34$), renal artery stenosis (OR
18 1.50, 95%CI 0.06-36.97, $p=0.80$), hypertensive crisis (OR 0.65, 95%CI 0.30-1.38, $p=0.26$) and
19 all-cause death (OR 1.76, 95%CI 0.34-9.20, $p=0.50$) between RDN and sham groups. Change of
20 renal function based on eGFR was comparable between groups (p for interaction 0.84). There
21 was significant heterogeneity between trials.

1 **Conclusions:** RDN safely reduces ambulatory and office SBP/DBP vs. a sham procedure in the
2 presence and absence of antihypertensive medication.

3

4 **Clinical Perspective**

5 What is new?

6 • Several sham-controlled trials have investigated the efficacy and safety of catheter-based
7 renal denervation (RDN) with mixed outcomes.

8 • This comprehensive meta-analysis comprising 2,478 patients shows that irrespective of
9 the utilized method (radiofrequency-, ultrasound- or alcohol-mediated), renal denervation
10 effectively reduced ambulatory and office systolic blood pressure.

11 • Renal denervation exhibited no additional risk concerning vascular injury or renal
12 function impairment.

13 What are the clinical implications?

14 • This meta-analysis supports current guidelines/consensus statements that renal
15 denervation represents an additive treatment option in carefully selected patients with
16 uncontrolled hypertension.

17

18

19

20

21

1 **Introduction**

2 Renal denervation (RDN) reduces blood pressure (BP) by modulating efferent and afferent
3 sympathetic renal nerve activity.¹ Although early unblinded studies suggested a pronounced BP-
4 lowering effect of RDN in patients with severe treatment-resistant hypertension², the first
5 generation of sham-controlled randomized trials³⁻⁵ was unable to prove the BP-lowering efficacy
6 of radiofrequency (RF) RDN using a mono-electrode catheter compared with a sham procedure.
7 Several procedural and methodological confounders were identified and subsequently addressed
8 by well-designed second-generation sham-controlled trials.⁶⁻¹¹ Moreover, human cadaveric
9 anatomical studies provided important insights into renal sympathetic nerve distribution and
10 density that informed the design of revised procedural techniques and technologies.^{12, 13} These
11 second-generation clinical trials utilized refined catheter systems, such as multi-electrode RF,
12 ultrasound, and alcohol-mediated RDN, in patients with mild-to-moderate hypertension in the
13 presence and absence of antihypertensive medications to resistant hypertension despite single-
14 pill triple agent combination therapy.¹⁴⁻¹⁸ Previous meta-analyses of sham-controlled trials
15 investigating the Spyril and Paradise RDN catheter systems¹⁹ and a subgroup analysis (with
16 sham-controlled trials) of another meta-analysis²⁰ consistently showed that RDN reduced office
17 and 24-hour SBP. We performed an updated comprehensive meta-analysis on summary data
18 from all published randomized, sham-controlled clinical trials investigating the effects of RDN
19 on BP across different devices.

20 **Methods**

21 **Eligibility criteria, literature search, and study selection**

22 A meta-analysis of the published randomized, sham-controlled trials (RCTs) was performed in
23 line with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA)

1 statement.²¹ The protocol for this analysis has been registered at PROSPERO
2 (CRD42022376504). Eligible publications were searched in MEDLINE and Cochrane Library
3 from 01/2000 to 01/2024 using the following keywords and Medical Subject Headings (MeSH)
4 terms: [renal denervation OR renal sympathetic denervation AND randomized sham-controlled
5 clinical trial OR sham-controlled AND treatment arterial hypertension OR treatment
6 hypertension] (Supplement, Table 1 and 2). Furthermore, we had access to several randomized,
7 yet unpublished trials (Netrod RDN²², Iberis HTN²³, TARGET BP I²⁴) that have been released
8 at scientific meetings and were submitted for publication. These trials met the criteria for being
9 considered high-quality trials; therefore, we made the decision to include them in the present
10 analysis.

11 All randomized, sham-controlled trials investigating catheter-based RDN using various methods
12 of nerve ablation (radiofrequency, ultrasound, alcohol-mediated) in patients with hypertension
13 only were considered eligible. Two authors (DV and LL) reviewed the full texts of potentially
14 eligible studies, thereby cross-checking the presence of inclusion criteria. A reference manager
15 software (Zotero, Corporation for Digital Scholarship, Vienna, VA, USA) was used to remove
16 duplicate.

17 **Data extraction**

18 Two authors (DV, LL) extracted data of interest using a predefined template and assessed risk of
19 bias at study level using the revised Cochrane risk-of-bias tool (RoB 2.0)²⁵, under final
20 supervision of a third investigator (FM). For each included study we assessed the risk of bias for
21 the following domains: randomization process, deviation from intended intervention, reporting of
22 missing data, measurement of outcome, selection of the reported results, single or multicenter

1 trial. Each domain was judged as low, moderate or high risk of bias based on the results of the
2 assessment that were stated as support of judgement. To assess small-study effects, we planned
3 to use funnel plots if at least 10 trials were available. If asymmetry in the funnel plot was
4 detected, we planned to review the characteristics of the trials to assess whether the asymmetry
5 was likely due to publication bias or other factors such as methodological or clinical
6 heterogeneity of the trials.

7 The following data were extracted: i) baseline characteristics, study design, primary outcome,
8 duration of follow-up, sample size, utilized method of RDN and RDN device; ii) mean change
9 from baseline to primary endpoint assessment in office and ambulatory systolic and diastolic BP
10 (SBP/DBP), daytime and nighttime SBP/DBP, number of antihypertensive drugs at
11 randomization and at the time of primary endpoint assessment; iii) safety data, including the
12 number of events of all-cause death, vascular complication, renal artery stenosis >70%,
13 hypertensive crisis, stroke, hospitalization for heart failure (HF), embolic event, new end-stage-
14 renal-disease (ESRD) and mean change from baseline to primary endpoint assessment renal
15 function according to estimated glomerular filtration rate (eGFR by CKD-EPI).

16 **Outcomes of interest**

17 The main efficacy outcomes were between-group (RDN vs sham) difference concerning changes
18 from baseline in mean 24-hour SBP and DBP as well as office SBP and DBP. Additional
19 efficacy outcomes were changes from baseline in daytime and night-time SBP/DBP. Safety
20 outcomes included the between-group difference in incidence of previously mentioned safety
21 events and changes in eGFR. Furthermore, we compared the number of antihypertensive drugs at
22 the time of primary endpoint assessment between the groups, to assess whether RDN may impact

1 medication burden. Also, we looked for the number of patients who met escape criteria and
2 experienced antihypertensive medication adjustments (addition/cessation of new drugs or
3 changes in drug doses) due to very high or low BP values during or after the follow-up in the
4 included trials.

5 **Statistical analysis**

6 A study-level, pairwise, random-effects meta-analysis was performed based on the intention-to-
7 treat or modified intention-to-treat analysis (depending on how data were reported) of the
8 summary data. For efficacy outcomes, we pooled the mean changes of BP with its corresponding
9 SD at the time of primary outcome assessment and applied the inverse variance statistical
10 method. If SD was not reported in the trials, we used the reported 95% confidence intervals (CI)
11 or the standard error of the mean (SEM) to calculate SD. For safety outcomes, we determined
12 odds ratios (ORs) by applying the Mantel-Haenszel method. In case the outcomes had
13 documented null events in one arm (RDN or sham), a fixed value (typically 0.5) would be added
14 (routinely performed by software included in RevMan) to avoid computational error.²⁶
15 Heterogeneity between the trials was assessed using Cochran's Q test and I^2 statistic. Relevant
16 statistical heterogeneity was assumed if $I^2 > 50\%$. In case of relevant heterogeneity for main
17 outcomes, jackknife sensitivity analyses, such as running the analysis after excluding each trial
18 in turn would have been performed to identify outliers. To increase the reliability of the summary
19 findings, we only included high-quality trials according to our assessment and in accordance
20 with the European Society of Cardiology (ESC) Council on Hypertension and the European
21 Association of Percutaneous Cardiovascular Interventions (EAPCI) clinical consensus statement
22 in the main analyses.⁶ As part of sensitivity analyses, all eligible trials were included for which
23 main (change of ambulatory and office SBP and DBP) and additional efficacy outcomes like

1 change of day- and nighttime SBP/DBP were analyzed. To evaluate the long-term efficacy of
2 RDN, we pooled the longest available follow-up 24-hour and office SBP data.

3 Further subgroup analyses were conducted to investigate the potential moderator effects of
4 certain factors on the ultimate outcomes regarding the primary efficacy measures. These
5 included only high-quality trials as defined by the ESC/EAPCI clinical consensus document. We
6 determined p for interaction/heterogeneity²⁷ concerning effects of RDN on ambulatory and
7 office systolic/diastolic BP between trials in the following settings: effects of RDN in the
8 presence and absence of antihypertensive medication (i.e., ON- and OFF-medication trials
9 design), first-generation RF device vs second-generation devices, and RDN modality (i.e. radio-
10 frequency vs ultrasound ablation vs alcohol-mediated techniques). Study-specific and summary
11 effect estimates with corresponding 95% confidence intervals (CIs) and p-values were visualized
12 using forest plots. All statistical analyses were performed using RevMan Version 5.4 (The
13 Cochrane Collaboration, Copenhagen, Denmark) and GraphPad Prism Version 6 (GraphPad
14 Software, Boston, Massachusetts, USA). All p-values were two-sided, with p less than 0.05
15 considered significant.

16 **Results**

17 The search identified 145 records (Supplement, Figure 1), of which 13 trials were considered
18 eligible. Ten trials^{3, 16-18, 22-24, 28-30} comprising 2,478 patients, were graded as high-quality trials
19 (Supplement, Table 3-15) (Table 1). Three additional randomized, sham-controlled trials^{4, 5, 31}
20 graded as moderate risk of bias⁶ were added to the main analysis and analyzed as a part of
21 sensitivity analysis comprising 2,690 patients. Long-term data on 24-hour and office SBP were
22 available for 5 trials.³²⁻³⁴ The baseline characteristics of all trials are summarized in Table 1.
23 Small study effects have been evaluated using funnel plots for following outcomes: 24-hour

1 SBP/DBP and office SBP/DBP. ³⁵ The median follow-up duration to primary endpoint
2 assessment was 3 months, ranging from 2 to 6 months across trials.

3 **Effects of renal denervation on ambulatory blood pressure**

4 Independent of the method utilized for renal nerve ablation and compared with a sham
5 procedure, RDN reduced mean 24-hour ambulatory SBP by -4.4 mmHg (95% CI -6.1, -2.7,
6 $p<0.00001$, Figure 1) as well as 24-hour ambulatory DBP by -2.6 mmHg (95% CI -3.6, -1.5,
7 $p<0.00001$, Figure 1). There was relevant heterogeneity for both 24-hour ambulatory SBP and
8 DBP ($I^2=68%$, and $I^2=60%$, respectively). The Iberis-HTN ²³ and Netrod RDN ²² trials were
9 identified as sources of heterogeneity. After excluding these trials, heterogeneity was no longer
10 present (SBP, $I^2=5%$; DBP, $I^2=42%$) and the 24-hour ambulatory SBP/DBP reductions vs. sham
11 remained statistically significant (mean difference for 24-hour SBP: -3.3 mmHg, 95% CI -4.3, -
12 2.2, $p<0.00001$; mean difference for 24-hour DBP: -2.0 mmHg, 95% CI -2.9, -1.0, $p<0.0001$).
13 Funnel plots for 24-hour SBP and DBP showed no signs of asymmetry (Supplement, Figure 2A
14 and 2B).

15 **Effects of renal denervation on office blood pressure**

16 Office SBP and DBP was significantly reduced following RDN (mean difference vs. sham: -6.6
17 mmHg, 95% CI -9.7, -3.6, $p<0.0001$ and -3.5 mmHg, 95% CI -5.4, -1.6, $p=0.0003$, respectively)
18 with relevant heterogeneity ($I^2=82%$, Figure 2). The Netrod RDN ²² trial was identified as a
19 source of heterogeneity for office SBP and Netrod RDN ²² and TARGET BP I ²⁴ trials for office
20 DBP. After omitting the data from Netrod RDN ²² for SBP and both trials for DBP, the
21 heterogeneity was no longer present with a sustained relevant reduction in systolic and diastolic
22 BP (-5.2 mmHg, 95% CI -6.5, -3.8, $p<0.00001$, $I^2=0%$; -3.1 mmHg, 95% CI -4.0, -2.2,

1 $p < 0.00001$, $I^2 = 0\%$, respectively). Funnel plot for office SBP showed presence of asymmetry
2 caused by statistical heterogeneity (Supplement, Figure 3A). The outcomes of the Netrod RDN²²
3 trial were the cause of heterogeneity due the extensive office SBP reductions reported herein.
4 Funnel plot for DBP showed no signs of asymmetry (Supplement, Figure 3B).

5 **Effects of renal denervation on daytime and nighttime blood pressure**

6 RDN reduced daytime SBP (mean difference vs. sham: -5.2 mmHg, 95% CI -7.6, -2.8,
7 $p < 0.0001$) with relevant heterogeneity ($I^2 = 76\%$) and daytime DBP (mean difference vs. sham: -
8 2.9 mmHg, 95% CI -4.5, -1.3, $p = 0.0004$) with relevant heterogeneity ($I^2 = 73\%$; Figure 3). When
9 data from the Iberis-HTN²³ and Netrod RDN²² trial were excluded, the relevant heterogeneity
10 for daytime SBP was still present ($I^2 = 51\%$) and a significant SBP reduction observed (mean
11 difference vs. sham: -3.6 mmHg, 95% CI -5.5, -1.7, $p = 0.0002$). Nighttime SBP was also
12 significantly reduced by RDN (mean difference vs. sham: -4.5 mmHg, 95% CI -6.1, -2.8,
13 $p < 0.00001$) without relevant heterogeneity ($I^2 = 32\%$). Nighttime DBP paralleled these findings
14 (mean difference vs. sham -2.6 mmHg, 95% CI -3.7, -1.5, $p < 0.00001$) without heterogeneity
15 ($I^2 = 30\%$; Figure 4).

16 **Effects of renal denervation on heart rate**

17 The changes of 24-hour ambulatory heart rate at the time of primary endpoint collection
18 compared with baseline were reported in five trials.^{3, 17, 18, 22, 24, 28} Heart rate was mildly lowered
19 in the RDN groups (mean difference vs. baseline -2 beats per minute, 95% CI -3.7, -0.2, $p = 0.03$)
20 but not the sham group (mean difference vs. baseline -1.3 beats per minute, 95% CI -3.2, 0.6,
21 $p = 0.18$), without relevant heterogeneity between groups (p for interaction 0.64) (Supplement,
22 Figure 4).

1 **Sensitivity analysis with long-term data for 24-hour and office SBP**

2 Exploring the long-term data from the SYMPPLICITY HTN-3 (36-months of follow up),
3 SPYRAL HTN-ON MED (36-months of follow up), and RADIANCE-HTN and RADIANCE II
4 trials (6-months of follow up) together with other high-quality trials, RDN reduced 24-hour SBP
5 (mean difference -5.4 mmHg, 95% CI -7.8, -3, $p<0.00001$) and office SBP (mean difference -6.9
6 mmHg, 95% CI -11.2, -2.6, $p=0.001$), both with relevant heterogeneity ($I^2=72%$, for 24-hour
7 SBP; $I^2=86%$, for office SBP) (Supplement, Figure 5). Of note, after the primary outcome
8 assessment, in certain trials, patients were unblinded and medication changes were allowed to
9 achieve BP control.

10 **Sensitivity analysis with all eligible trials**

11 When performing a sensitivity analysis with all published sham-controlled trials, including those
12 not fulfilling the quality criteria of the ESC/EAPCI clinical consensus statement, RDN reduced
13 24-hour SBP (mean difference vs. sham: -4.0 mmHg, 95% CI -5.5, -2.4, $p<0.00001$) and 24-
14 hour DBP (mean difference vs. sham: -2.1 mmHg, 95% CI -3.1, -1.1, $p<0.0001$), both with
15 relevant heterogeneity ($I^2=62%$ for SBP; $I^2=60%$ for DBP) (Supplement, Figure 6). RDN also
16 reduced office SBP (mean difference vs. sham: -6.3 mmHg, 95% CI -9.2, -3.4, $p<0.0001$) and
17 DBP (mean difference vs. sham: -3.2 mmHg, 95% CI -5.0, -1.4, $p=0.0005$) with relevant
18 heterogeneity ($I^2=80%$ for SBP; $I^2=81%$ for DBP) (Supplement, Figure 7).

19 RDN reduced daytime SBP (mean difference vs. sham:-4.6 mmHg, 95% CI -6.8, -2.6,
20 $p<0.00001$) and DBP (mean difference vs. sham: -2.4 mmHg, 95% CI -3.7, -1.0, $p=0.0005$) with
21 relevant heterogeneity ($I^2=68%$ for SBP; $I^2=67%$ for DBP) (Supplement, Figure 8). RDN also
22 reduced nighttime SBP (mean difference vs. sham:-3.5 mmHg, 95% CI -5.4, -1.7, $p=0.0001$) and

1 DBP (mean difference vs. sham: -1.6 mmHg, 95% CI -3.0, -0.2, $p=0.02$) with relevant
2 heterogeneity ($I^2=48\%$ for SBP; $I^2=59\%$ for DBP) (Supplement, Figure 9).

3 **Effects of renal denervation in the absence or presence of antihypertensive medications**

4 There was no relevant difference in 24-hour SBP reduction with RDN vs. sham between trials
5 with or without concomitant antihypertensive medications (-4.8 mmHg, 95% CI -7.7, -2.0,
6 $p=0.001$, $I^2=79\%$ vs. -4.0 mmHg, 95% CI -5.7, -2.3, $p<0.00001$, $I^2=32\%$, respectively; p for
7 interaction 0.62) (Supplement, Figure 10). Similar outcomes were observed for 24-hour DBP
8 reductions (Supplement, Figure 10). There were neither relevant differences in office SBP and
9 DBP reduction between trials with or without concomitant antihypertensive drugs (Supplement,
10 Figure 11) nor were there relevant differences concerning the number of antihypertensive
11 medications prescribed during follow-up (Supplement, Figure 12).

12 There were more patients in the sham than in the RDN groups with medication adjustments due
13 to safety concerns of meeting escape BP levels (Supplement, Table 16).

14 **Effects of renal denervation with first- versus second-generation devices**

15 The magnitude of 24-hour SBP and DBP reduction with RDN vs. sham between second-
16 generation versus first-generation RDN devices was not significantly different (SBP: -4.7/-2.0
17 and DBP: -2.7/-1.0 mmHg, respectively, p for interaction $p=0.14$ for SBP and $p=0.11$ for DBP)
18 (Supplement, Figure 13). Similar findings were observed for office SBP (p for interaction 0.10)
19 and DBP (p for interaction 0.30) between second-generation versus first-generation RDN devices
20 (Supplement, Figure 14).

21 **Effects of radiofrequency-, ultrasound- and alcohol-mediated renal denervation devices**

1 Ambulatory SBP and DBP were significantly reduced in trials investigating RF (mean difference
2 vs sham: -5.2 mmHg, $p=0.001$ and -2.8 mmHg, $p=0.0007$, respectively), and ultrasound RDN
3 (mean difference vs. sham: -4.8 mmHg, $p<0.00001$ and -2.5 mmHg, $p=0.02$, respectively).
4 Ambulatory SBP was also significantly reduced in alcohol-mediated RDN trials (mean
5 difference -2.4 mmHg, $p=0.03$), but not DBP (mean difference vs. sham:-1.7 mmHg, $p=0.09$).
6 There was no relevant interaction between subgroups concerning ambulatory SBP (p for
7 interaction 0.18) and DBP (p for interaction 0.72) (Supplement, Figure 15).

8 Office SBP was significantly reduced in trials with RF (mean difference vs. sham: -7.9 mmHg,
9 $p=0.004$), ultrasound (mean difference vs. sham: -6.1 mmHg, $p<0.0001$) and alcohol-mediated
10 RDN (mean difference vs. sham: -3.6 mmHg, $p=0.02$), respectively. Similarly, office DBP was
11 significantly reduced in trials with RF (mean difference vs. sham: -4.6 mmHg, $p=0.001$),
12 ultrasound (mean difference vs. sham: -3.6 mmHg, $p=0.0001$) but not alcohol-mediated RDN
13 (mean difference vs. sham: -0.4 mmHg, $p=0.85$), respectively. There was no relevant interaction
14 between subgroups concerning systolic (p for interaction 0.32) and diastolic BP (p for interaction
15 0.18) (Supplement, Figure 16).

16 **Safety outcomes**

17 There was no significant difference in the predefined safety outcomes between the RDN and
18 sham groups (Table 2). For all safety outcomes, there were no signs of heterogeneity ($I^2=0\%$).
19 Furthermore, there was no significant interaction (p for interaction 0.90) regarding change in
20 renal function assessed by change in eGFR from baseline between the RDN (-0.75 ml/min/1.73
21 m^2 , 95% CI -2.0, 0.5, $p=0.24$) and sham groups (-0.62 ml/min/1.73 m^2 , 95% -2.2, 1.0, $p=0.43$)
22 (Supplement, Figure 17).

1 **Discussion**

2 In this comprehensive, updated meta-analysis, catheter-based RDN was associated with
3 significantly reduced office and 24-hour BP, including daytime and nighttime SBP and DBP.
4 Subgroup analyses indicated no relevant differences in BP-lowering efficacy regardless of
5 whether individuals were taking or not antihypertensive medication at baseline, or the method or
6 device employed for renal nerve ablation. Moreover, adverse safety events were rare and
7 comparable between the RDN and sham groups.

8 Hypertension represents the leading modifiable cause of death worldwide.³⁶ The absolute
9 number of people with hypertension is increasing globally and is estimated to reach 1.5 billion
10 by 2025.³⁷ Despite the availability of effective antihypertensive drugs³⁸, guideline-
11 recommended BP targets are often not achieved.^{37, 39} Device-based antihypertensive treatments
12 have been developed as adjunct treatment options in addition to lifestyle interventions and drugs.
13⁴⁰ Several randomized, sham-controlled clinical trials have shown the ability of catheter-based
14 RDN to lower BP in patients with and without antihypertensive medication with mixed
15 outcomes.^{14-18, 28} Herein, RDN was associated with significantly reduced office and ambulatory
16 BP, including daytime and nighttime BP. The latter has been strongly associated with
17 cardiovascular morbidity and mortality.⁴¹

18 This meta-analysis reports modest but clinically meaningful 24-hour and office SBP reductions
19 of 4.4 mmHg and 6.6 mmHg, respectively. A sensitivity analysis of long-term data suggests that
20 the BP decrease was maintained, if not even continued, following primary outcome assessment
21 after 2-6 months. Indeed, an individual-patient level meta-analysis has shown that a 5 mmHg-
22 reduction in office SBP with antihypertensive drugs reduced the risk for major cardiovascular

1 events (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial
2 infarction or ischemic heart disease or heart failure causing death or requiring hospital
3 admission) by 10%, regardless of previously diagnosed cardiovascular disease and even in
4 participants with normal or high-normal BP.⁴²

5 Given the safety and efficacy of RDN, the 2022 ESC Clinical Consensus Statement, the 2023
6 European Society of Hypertension Guidelines and the 2023 SCAI consensus statement⁴³
7 recommend that RDN can be considered in patients with resistant hypertension and preserved
8 renal function (eGFR >40 ml/min/1.73 m²).^{6, 44} In line with the 2023 ESH Guidelines for the
9 management of arterial hypertension and the 2022 ESC Clinical Consensus Statements, RDN
10 represents an alternative treatment option for patients with resistant hypertension but also
11 patients with uncontrolled hypertension on fewer drugs if first-line drugs are either not tolerated
12 or patients are non-adherent.⁶ For most patients, initial antihypertensive therapy should be
13 centered on medications that have been demonstrated to decrease cardiovascular events and
14 mortality.⁶ Importantly, the decision-making process should involve a multidisciplinary
15 hypertension team and consider the preference of a well-informed patient. Additionally, in the
16 presence of high cardiovascular risk or hypertension-mediated organ damage, RDN should be
17 considered as an additional approach.⁶ However, it is essential to emphasize that patients must
18 be thoroughly informed by their treating physicians about the potential risks of the invasive
19 procedure. The findings from this meta-analysis support these recommendations since RDN was
20 associated with clinically relevant BP reductions in trials with and without concomitant
21 antihypertensive medication and irrespective of the utilized RDN-modality (RF-, ultrasound- or
22 alcohol-mediated). Thus, these data strongly underpin that RDN as a mechanism earned its
23 unequivocal role in BP control in hypertensive patients.

1 There was a relevant statistical heterogeneity in several endpoints (24-hour SBP/DBP, office
2 SBP/DBP). According to the sensitivity analysis, the Netrod RDN trial ²² alone (for the
3 endpoints office SBP and DBP) and in combination with the Iberis-HTN trial ²³ (for the endpoint
4 24-hour SBP) have been identified as sources of heterogeneity due to numerically greater BP
5 reductions following RDN when compared with other trials. One may speculate that this is
6 related to the population included since both trials were conducted in China and studied patients
7 with different background medication, severity of hypertension, and ethnicity. The Iberis-HTN
8 trial, for instance, purposely included younger patients (mean age 45 years) with elevated heart
9 rate (mean of 79 bpm). It has been suggested that RDN may be more effective in younger
10 patients because of a lower incidence of arterial stiffness and an increased sympathetic tone as
11 the leading mechanism of hypertension. ⁴⁵ However, in trials encompassing patients [across a](#)
12 [wider age spectrum](#), such as the Radiance HTN trials (which included patients aged 20-75 years)
13 ³⁴, sensitivity analyses did not [indicate a significant](#) interaction between age and the BP lowering.
14 Overall, number of vascular complications events was very low (0.5% across all included
15 patients) and did not differ between RDN and sham groups. In a previous meta-analysis, the
16 annual incidence rate of renal artery³⁴ stent implantation following RF RDN was 0.2% ⁴⁶, which
17 appears comparable with the natural incidence of renal artery stenosis in patients with arterial
18 hypertension. ⁴⁷ While the analysis suggested a favorable safety profile for RDN, it is crucial to
19 [note that the procedures were carried out by experienced physicians, and the data are derived](#)
20 [from a relatively small patient cohort.](#)

21 **Limitations**

1 All included trials excluded patients with known secondary hypertension. Most trials excluded
2 patients with isolated systolic hypertension; thus, limiting generalizability to this hypertension
3 phenotype. However, data from the Global Symplcity Registry ⁴⁸ and a single-center
4 randomized controlled trial comparing different catheter technologies ⁴⁹ suggest that the BP
5 reductions following RDN are not different between patients with isolated systolic hypertension
6 and combined systolic-diastolic hypertension. The maximal follow-up for the assessment of the
7 primary outcome was 6 months. Trials including drug-naïve patients or requiring a washout of
8 antihypertensive drugs had even shorter follow-up durations of 2 to 3 months. The possibility of
9 reinnervation of the renal sympathetic nerves raised the question of whether this would mitigate
10 the effects on BP at the long term. Preclinical studies showed partial, but non-functional, nerve
11 regrowth 30 months after RDN in sheep ⁵⁰ and sustained denervation after 180 days in porcine
12 models. ⁵¹ Investigating longer-term follow-up is challenging due to several factors. These
13 include the unblinding of patients and outcome assessors, potential crossover of sham patients to
14 RDN, age- and body weight-dependent longitudinal BP changes, the addition of antihypertensive
15 medications to facilitate BP control, and dynamic changes in drug adherence over time. ⁶ In line,
16 the long-term three years results from the Global SYMPLICITY Registry ⁵², the SPYRAL HTN-
17 ON MED³³, the RADIANCE-HTN SOLO ⁵³ and the SYMPLICITY HTN-3 ³² trials
18 demonstrated sustained and even progressive effects for at least 3 years. Results of our
19 sensitivity analysis with long-term data of these hallmark trials support these findings. Moreover,
20 this study-level meta-analysis is not based on individual patient data which limits the possibility
21 of performing more detailed subgroup analysis to identify predictors of BP response to RDN.

22 **Conclusion**

1 This comprehensive meta-analysis of ten randomized sham controlled trials comprising 2,478
2 patients demonstrated that catheter-based RDN safely reduced 24-hour and office BP up to 6
3 months compared with sham in hypertensive patients with and without concomitant
4 antihypertensive medication irrespective of the utilized RDN modality.

5 **Acknowledgements**

6 None.

7 **Funding**

8 ERE is funded in part by R01HL161069 from the US National Institutes of Health

9 None.

10 **Conflicts of interest**

11 DV has no disclosures related to this article. ERE was supported, in part, by the NIH (R01
12 HL161069). LL received speaker honoraria from AstraZeneca, Medtronic, Pfizer, and ReCor
13 Medical. FM is supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche
14 Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung.
15 Saarland University has received scientific support from Ablative Solutions, Medtronic and
16 ReCor Medical. Until May 2024, FM has received speaker honoraria/consulting fees from
17 Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic,
18 Merck, ReCor Medical, Servier, and Terumo. DLB discloses the following relationships -
19 Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific,
20 Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape
21 Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys;

1 Board of Directors: American Heart Association New York City, Angiowave (stock options),
2 Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock); Consultant:
3 Broadview Ventures, Hims, SFJ, Youngene; Data Monitoring Committees: Acesion Pharma,
4 Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard
5 Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott),
6 Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair,
7 PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of
8 Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial,
9 funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis,
10 Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);
11 Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News,
12 ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work
13 related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical
14 Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering
15 committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL
16 Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and
17 Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL
18 Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial
19 steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals),
20 HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College
21 of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum),
22 Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone
23 CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler,

1 Population Health Research Institute (for the COMPASS operations committee, publications
2 committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME
3 steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor);
4 Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's
5 Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any
6 income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker
7 Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim,
8 Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi,
9 CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring
10 Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood,
11 Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed,
12 Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron,
13 Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company,
14 Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald's Heart Disease); Site Co-Investigator:
15 Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips,
16 SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded
17 Research: FlowCo. RES received speaker and advisor honoraria from Ablative Solutions,
18 Medtronic, and Recor and grants to the Institution from Ablative Solution, Medtronic and Recor.
19 DEK discloses the following relationships: personal consulting honoraria: Medtronic, Ablative
20 Solutions, HyperQure; Institutional Research/Grant Support: Ablative Solutions, Biotronik,
21 Medtronic, Orchestra Biomed, Orbus Neich, Teleflex; Equity: BioStar Ventures (none related to
22 Ablative Solutions). MB is supported by the Deutsche Forschungsgemeinschaft (German
23 Research Foundation; TTR 219, project number 322900939) and reports personal fees from

- 1 Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic,
- 2 Novartis, Recor, Servier and Vifor. MA reports receiving grants from the European Horizon
- 3 2020 program; grants from Recor Medical, Idorsia, Novartis and AstraZeneca; and personal fees
- 4 from Alnylam Pharmaceuticals, Recor Medical Cincor, Medtronic, AstraZeneca, and Novartis.
- 5 All other authors have nothing to declare.

1 **References**

- 2 1. DiBona GF. Physiology in perspective: The Wisdom of the Body. Neural control of the
3 kidney. *Am J Physiol Regul Integ Comp Physiol*. 2005;289:R633-41.
- 4 2. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R
5 and Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension:
6 final 3-year report of the Symplicity HTN-1 study. *Lancet*. 2014;383:622-9.
- 7 3. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB,
8 Liu M, Mauri L, Negoita M, et al. A controlled trial of renal denervation for resistant
9 hypertension. *N Engl J Med*. 2014;370:1393-401.
- 10 4. Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, Lederballe
11 O, Rickers H, Kampmann U, Poulsen PL, et al. Renal denervation in treatment-resistant essential
12 hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial.
13 *J Hypertens*. 2016;34:1639-47.
- 14 5. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller
15 U, Schuler G, Eitel I, et al. Randomized sham-controlled trial of renal sympathetic denervation in
16 mild resistant hypertension. *Hypertension*. 2015;65:1202-8.
- 17 6. Barbato E, Azizi M, Schmieder RE, Lauder L, Böhm M, Brouwers S, Bruno RM, Dudek
18 D, Kahan T, Kandzari DE, et al. Renal denervation in the management of hypertension in adults.
19 A clinical consensus statement of the ESC Council on Hypertension and the European
20 Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*. 2023;44:1313-
21 1330.
- 22 7. Kandzari DE, Mahfoud F, Weber MA, Townsend R, Parati G, Fisher NDL, Lobo MD,
23 Bloch M, Böhm M, Sharp ASP, et al. Clinical Trial Design Principles and Outcomes Definitions

- 1 for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension
2 Academic Research Consortium. *Circulation*. 2022;145:847-863.
- 3 8. Mahfoud F, Azizi M, Ewen S, Pathak A, Ukena C, Blankestijn PJ, Böhm M, Burnier M,
4 Chatellier G, Durand Zaleski I, et al. Proceedings from the 3rd European Clinical Consensus
5 Conference for clinical trials in device-based hypertension therapies. *Eur Heart J*. 2020;41:1588-
6 1599.
- 7 9. Mahfoud F, Schmieder RE, Azizi M, Pathak A, Sievert H, Tsioufis C, Zeller T, Bertog S,
8 Blankestijn PJ, Böhm M, et al. Proceedings from the 2nd European Clinical Consensus
9 Conference for device-based therapies for hypertension: state of the art and considerations for
10 the future. *Eur Heart J*. 2017;38:3272-3281.
- 11 10. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K,
12 Andersson B, Blankestijn PJ, Burnier M, et al. Proceedings from the European clinical consensus
13 conference for renal denervation: considerations on future clinical trial design. *Eur Heart J*.
14 2015;36:2219-27.
- 15 11. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT,
16 Lea J, Lee DP, et al. Predictors of blood pressure response in the SYMPPLICITY HTN-3 trial.
17 *Eur Heart J*. 2015;36:219-27.
- 18 12. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani
19 R and Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. *J Am Coll*
20 *Cardiol*. 2014;64:635-43.
- 21 13. Struthoff H, Lauder L, Hohl M, Hermens A, Tzafiriri AR, Edelman ER, Kunz M, Böhm
22 M, Tschernig T and Mahfoud F. Histological examination of renal nerve distribution, density,
23 and function in humans. *EuroIntervention*. 2023;19:612-620.

- 1 14. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S,
2 Tsioufis K, Tousoulis D, Sharp ASP, et al. Catheter-based renal denervation in patients with
3 uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF
4 MED): a randomised, sham-controlled, proof-of-concept trial. *Lancet*. 2017;390:2160-2170.
- 5 15. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K,
6 Tousoulis D, Choi JW, East C, et al. Effect of renal denervation on blood pressure in the
7 presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-
8 ON MED proof-of-concept randomised trial. *Lancet*. 2018;391:2346-2355.
- 9 16. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K,
10 Pocock S, Konstantinidis D, Choi JW, et al. Efficacy of catheter-based renal denervation in the
11 absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre,
12 randomised, sham-controlled trial. *Lancet*. 2020;395:1444-1451.
- 13 17. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane
14 AJ, Wang Y, Lobo MD, et al. Endovascular ultrasound renal denervation to treat hypertension
15 (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-
16 controlled trial. *Lancet*. 2018;391:2335-2345.
- 17 18. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J,
18 Bloch MJ, et al. Ultrasound renal denervation for hypertension resistant to a triple medication
19 pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
20 *Lancet*. 2021;397:2476-2486.
- 21 19. Stavropoulos K, Patoulias D, Imprialos K, Doumas M, Katsimardou A, Dimitriadis K,
22 Tsioufis C and Papademetriou V. Efficacy and safety of renal denervation for the management of

- 1 arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled,
2 catheter-based trials. *J Clin Hypertens (Greenwich)*. 2020;22:572-584.
- 3 20. Agasthi P, Shipman J, Arsanjani R, Ashukem M, Girardo ME, Yerasi C, Venepally NR,
4 Fortuin FD and Mookadam F. Renal Denervation for Resistant Hypertension in the
5 contemporary era: A Systematic Review and Meta-analysis. *Sci Rep*. 2019;9:6200.
- 6 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer
7 L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline
8 for reporting systematic reviews. *BMJ*. 2021;372:n71.
- 9 22. Zhou Y-J. Effectiveness and Safety of the Netrod™ Six-Electrode Radiofrequency Renal
10 Denervation System for the Treatment of Uncontrolled Essential Hypertension. *Paper presented*
11 *at: EURO PCR, May 17, 2023; Paris, France 2023.*
- 12 23. X Jiang, Rao G. Effectiveness and Safety of The Multi-Electrode Iberis Radiofrequency
13 Renal Denervation System for the treatment of Uncontrolled Primary Hypertension (Iberis-HTN
14 study). *Paper presented at: China Interventional Therapeutics (CIT); June 29 - July 2, 2023.*
15 *Beijing, China.*
- 16 24. Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, Schmieder RE,
17 Janas AJ, Langer C, Persu A, et al. Effect of Alcohol-Mediated Renal Denervation on Blood
18 Pressure in the Presence of Antihypertensive Medications: Primary Results from the TARGET
19 BP I Randomized Clinical Trial. *Circulation*. 2024 Apr 8. Online ahead of print.
- 20 25. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng
21 HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in
22 randomised trials. *BMJ*. 2019;366:l4898.

- 1 26. Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-
2 analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
3 VA. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.4 (updated August
4 2023). Cochrane, 2023.
- 5 27. Altman DG and Bland JM. Interaction revisited: the difference between two estimates.
6 *BMJ*. 2003;326:219.
- 7 28. Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder
8 RE, Mahfoud F, Lindsey J, et al. Endovascular Ultrasound Renal Denervation to Treat
9 Hypertension: The RADIANCE II Randomized Clinical Trial. *JAMA*. 2023;329:651-661.
- 10 29. Pathak A, Rudolph UM, Saxena M, Zeller T, Müller-Ehmsen J, Lipsic E, Schmieder RE,
11 Sievert H, Halbach M, Sharif F, et al. Alcohol-mediated renal denervation in patients with
12 hypertension in the absence of antihypertensive medications. *EuroIntervention*. 2023;19:602-
13 611.
- 14 30. Kandzari DE, Townsend RR, Kazuomi Kario, Felix Mahfoud, Michael A Weber, Roland
15 E Schmieder, Stuart Pocock, Konstantinos Tsioufis, Dimitrios Konstantinidis, James Choi, et al,
16 on behalf of the SPYRAL HTN-ON MED Investigators*. Safety and Efficacy of Renal
17 Denervation in the Presence of Antihypertensive Medications: SPYRAL HTN-ON MED. *J Am*
18 *Coll Cardiol*. 2023;82:1809-1823.
- 19 31. Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, Urata H, Cho
20 JM, Kim CJ, Choi SH, et al. Catheter-based ultrasound renal denervation in patients with
21 resistant hypertension: the randomized, controlled REQUIRE trial. *Hypertens Res*. 2022;45:221-
22 231.

- 1 32. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR,
2 Katzen BT, Oparil S, Brar S, DeBruin V, et al. Long-term outcomes after catheter-based renal
3 artery denervation for resistant hypertension: final follow-up of the randomised SYMPPLICITY
4 HTN-3 Trial. *Lancet*. 2022;400:1405-1416.
- 5 33. Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, Tsioufis
6 K, Pocock S, Dimitriadis K, Choi JW, et al. Long-term efficacy and safety of renal denervation
7 in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-
8 controlled trial. *Lancet*. 2022;399:1401-1410.
- 9 34. Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F,
10 Schmieder RE, Basile J, et al. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal
11 Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE
12 Clinical Trial Program. *Circulation*. 2024;149:747-759.
- 13 35. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G,
14 Harbord RM, Schmid CH, et al. Recommendations for examining and interpreting funnel plot
15 asymmetry in meta-analyses of randomised controlled trials. *BMJ*. 2011;343:d4002.
- 16 36. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic
17 analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1223-1249.
- 18 37. Worldwide trends in hypertension prevalence and progress in treatment and control from
19 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million
20 participants. *Lancet*. 2021;398:957-980.
- 21 38. Etehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J,
22 Rodgers A and Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and
23 death: a systematic review and meta-analysis. *Lancet*. 2016;387:957-967.

- 1 39. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL,
2 Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH Guidelines for the management of
3 arterial hypertension. *Eur Heart J*. 2018;39:3021-3104.
- 4 40. Lauder L, Azizi M, Kirtane AJ, Böhm M and Mahfoud F. Device-based therapies for
5 arterial hypertension. *Nat Rev Cardiol*. 2020;17:614-628.
- 6 41. Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, Ruiz-
7 Hurtado G, Segura J, Baigent C and Williams B. Relationship between clinic and ambulatory
8 blood pressure and mortality: an observational cohort study in 59 124 patients. *Lancet*.
9 2023;401:2041-2050.
- 10 42. Pharmacological blood pressure lowering for primary and secondary prevention of
11 cardiovascular disease across different levels of blood pressure: an individual participant-level
12 data meta-analysis. *Lancet*. 2021;397:1625-1636.
- 13 43. Swaminathan RV, East CA, Feldman DN, Fisher ND, Garasic JM, Giri JS, Kandzari DE,
14 Kirtane AJ, Klein A and Kobayashi T. SCAI position statement on renal denervation for
15 hypertension: patient selection, operator competence, training and techniques, and organizational
16 recommendations. *Journal of the Society for Cardiovascular Angiography & Interventions*.
17 2023;2:101121.
- 18 44. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML,
19 Tsioufis K, Agabiti-Rosei E, Algharably EAE, et al. 2023 ESH Guidelines for the management
20 of arterial hypertension The Task Force for the management of arterial hypertension of the
21 European Society of Hypertension Endorsed by the European Renal Association (ERA) and the
22 International Society of Hypertension (ISH). *J Hypertens*. 2023;41:1874-2071.

- 1 45. Böhm M, Tsioufis K, Kandzari DE, Kario K, Weber MA, Schmieder RE, Townsend RR,
2 Kulenthiran S, Ukena C, Pocock S, et al. Effect of Heart Rate on the Outcome of Renal
3 Denervation in Patients With Uncontrolled Hypertension. *J Am Coll Cardiol.* 2021;78:1028-
4 1038.
- 5 46. Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP, Blankestijn PJ,
6 Böhm M and Mancia G. Review and meta-analysis of renal artery damage following
7 percutaneous renal denervation with radiofrequency renal artery ablation. *EuroIntervention.*
8 2020;16:89-96.
- 9 47. Chrysochou C and Kalra PA. Epidemiology and natural history of atherosclerotic
10 renovascular disease. *Prog Cardiovasc Dis.* 2009;52:184-95.
- 11 48. Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, Whitbourn
12 R, Zirlik A, Zeller T, Stawowy P, et al. Renal Denervation in High-Risk Patients With
13 Hypertension. *J Am Coll Cardiol.* 2020;75:2879-2888.
- 14 49. Fengler K, Rommel KP, Lapusca R, Blazek S, Besler C, Hartung P, von Roeder M,
15 Kresoja KP, Desch S, Thiele H, et al. Renal Denervation in Isolated Systolic Hypertension Using
16 Different Catheter Techniques and Technologies. *Hypertension.* 2019;74:341-348.
- 17 50. Singh RR, McArdle ZM, Iudica M, Easton LK, Booth LC, May CN, Parkington HC,
18 Lombardo P, Head GA, Lambert G, et al. Sustained Decrease in Blood Pressure and Reduced
19 Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months
20 After Catheter-Based Renal Denervation. *Hypertension.* 2019;73:718-727.
- 21 51. Sharp ASP, Tunev S, Schlaich M, Lee DP, Finn AV, Trudel J, Hettrick DA, Mahfoud F
22 and Kandzari DE. Histological evidence supporting the durability of successful radiofrequency
23 renal denervation in a normotensive porcine model. *J Hypertens.* 2022;40:2068-2075.

1 52. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, Schlaich M,
2 Williams B, Fahy M and Mancia G. Effects of renal denervation on kidney function and long-
3 term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. *Eur Heart J.*
4 2019;40:3474-3482.

5 53. Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T, Scicli AP,
6 Thackeray L, et al. Durability of blood pressure reduction after ultrasound renal denervation:
7 three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.
8 *EuroIntervention.* 2022;18:e677-e685.

9

10

11

12

13

14

Table 1. Baseline characteristics of the included trials

Study and publication year	Study design	Sample size (RDN/Sham)	Inclusion criteria	Exclusion criteria	Primary efficacy endpoint	Catheter (Modality)	Link to the public trial registry
SYMPPLICITY HTN-3 2014 ³	Randomized 2:1, RDN vs. sham procedure, on med	364/171	18-80 y, severe resistant hypertension, office SBP >160 mmHg on ≥ 3 med	Known secondary hypertension, >1 hypertensive crisis, unsuitable renal artery anatomy, eGFR <45 ml/min/1.73 m ²	Change in office SBP after 6 months	Symplicity Flex (radiofrequency)	NCT01418261
Desch et al. 2014 ⁵	Randomized 1:1, RDN vs. sham procedure, on med	35/36	18-75 y, resistant hypertension, daytime BP 135-149/90-94 mmHg on ≥ 3 med	Severe comorbidities, unsuitable renal artery anatomy, eGFR <45 ml/min/1.73 m ²	Change in 24-h SBP after 6 months	Symplicity Flex (radiofrequency)	NCT01656096
ReSET 2016 ⁴	Randomized 1:1, RDN vs. sham procedure, on	36/33	30-70 y, resistant hypertension, daytime SBP	Secondary hypertension, congestive HF, unsuitable	Change in daytime ambulatory SBP after 3	Symplicity Flex (radiofrequency)	NCT01762488

Study and publication year	Study design	Sample size (RDN/Sham)	Inclusion criteria	Exclusion criteria	Primary efficacy endpoint	Catheter (Modality)	Link to the public trial registry
	med		>145 mmHg on ≥ 3 med	renal artery anatomy, eGFR ≤ 30 ml/min/1.73 m ²	months		
RADIANCE-HTN SOLO 2018 ¹⁷	Randomized 1:1, RDN vs. sham procedure, off med	74/72	18-75 y, office BP ≥ 140 / >90 and <180 / 110 mmHg	History of CV or cerebrovascular events, unsuitable renal artery anatomy, eGFR <40 ml/min/1.73 m ²	Change in daytime ambulatory SBP after 2 months	Paradise (ultrasound)	NCT02649426
SPYRAL HTN-OFF MED Pivotal 2020 ¹⁶	Randomized 1:1, RDN vs. sham procedure, off med	166/165	20-80 y, office SBP >150 mmHg and <180 mmHg, DBP >90 mmHg	Angina pectoris, MI within last 3 months, unsuitable renal artery anatomy, eGFR <45 ml/min/1.73 m ²	Change in 24-h SBP after 3 months	Spyral (radiofrequency)	NCT02439749
RADIANCE-	Randomized	69/67	18-75 y, office	History of	Change in	Paradise	NCT02649426

Study and publication year	Study design	Sample size (RDN/Sham)	Inclusion criteria	Exclusion criteria	Primary efficacy endpoint	Catheter (Modality)	Link to the public trial registry
HTN TRIO 2021 ¹⁸	1:1, RDN vs. sham procedure, on med		BP \geq 140/ $>$ 90 mmHg on 3-drug single-pill combination	cerebrovascular or severe CV event, unsuitable renal artery anatomy, eGFR $<$ 40 ml/min/1.73 m ²	daytime ambulatory SBP after 2 months	(ultrasound)	
TARGET BP OFF-MED 2022 ²⁹	Randomized 1:1, RDN vs. sham procedure, off med	50/56	18-80 y, office SBP 140-180 and DBP \geq 90 mmHg on 0-2 med.	eGFR $<$ 45 ml/min/1.73 m ² , severe HF, unsuitable renal anatomy	Change in 24-h SBP after 2 months	Peregrine (alcohol)	NCT03503773
REQUIRE 2022 ³¹	Randomized 1:1, RDN vs. sham procedure, on med	72/71	20-75 y, resistant hypertension with 3 med., BP $>$ 150/ $>$ 90 mmHg	eGFR $<$ 40 ml/min/1.73 m ² , secondary hypertension, chronic diseases, unsuitable renal artery anatomy	Change in 24-h SBP after 3 months	Paradise (ultrasound)	NCT02918305
RADIANCE II	Randomized	150/74	18-75 y, 24-h	eGFR $<$ 40	Change in	Paradise	NCT03614260

Study and publication year	Study design	Sample size (RDN/Sham)	Inclusion criteria	Exclusion criteria	Primary efficacy endpoint	Catheter (Modality)	Link to the public trial registry
2023 ²⁸	2:1, RDN vs. sham procedure, off med		BP \geq 135/85 and $<$ 170/105 mmHg	ml/min/1.73 m ² , unsuitable renal artery anatomy	daytime ambulatory SBP after 2 months	(ultrasound)	
SPYRAL HTN-ON MED (Pilot and Expansion phase) 2023 ³⁰	Randomized 1:1 for 106 patients and 2:1 for 231 subsequent patients, RDN vs. sham procedure, on med	206/131	20-80 y, 24-h SBP $>$ 140/90 mmHg on 1-3 drugs	Angina pectoris, MI within last 3 months, unsuitable renal artery anatomy, eGFR $<$ 45 ml/min/1.73 m ²	Change in 24-h SBP after 6 months	Spyral (radiofrequency)	NCT02439775
Iberis-HTN 2023 ²³	Randomized 1:1, RDN vs. sham procedure, on med	107/110	18-65 y, office SBP 150-180 mmHg and DBP \geq 90 mmHg on 3 med	eGFR $<$ 45 ml/min/1.73m ² , secondary hypertension, unsuitable renal artery anatomy	Change in 24-h SBP after 6 months	Iberis (radiofrequency)	NCT02901704
Netrod RDN 2023 ²²	Randomized 2:1, RDN vs. sham	139/66	18-65 y, office BP \geq 150/90 and $<$ 180/110	eGFR $<$ 45 ml/min/1.73m ² , secondary	Change in 24-h SBP at 6 months	Netrod (radiofrequency)	NCT03261375

Study and publication year	Study design	Sample size (RDN/Sham)	Inclusion criteria	Exclusion criteria	Primary efficacy endpoint	Catheter (Modality)	Link to the public trial registry
	procedure, off med		mmHg on ≥ 2 drugs	hypertension			
TARGET BP I 2024 ²⁴	Randomized 1:1, RDN vs. sham procedure, on med	148/153	18-80 y, office SBP ≥ 150 and < 180 mmHg on ≥ 2 drugs	eGFR < 45 ml/min/1.73m ² , secondary hypertension	Change in 24-h SBP at 3 months	Peregrine (alcohol)	NCT02910414

Abbreviations: CV, cardiovascular; DBP, diastolic blood pressure; FMD, fibromuscular dysplasia; HF, heart failure; RDN, renal denervation; med, medications; MI, myocardial infarction; SBP, systolic blood pressure; y, years.

Table 2. Safety endpoints across RDN and sham group

Endpoint	Number of studies with documented endpoint	Number of studies that specifically reported endpoint	RDN N (%)	Sham N (%)	Effect Estimate (OR with 95% CI)
Vascular complication	7	13	8 / 1,598 (0.5%)	2 / 1,197 (0.17%)	1.69, 0.57-5.0, p=0.34
Renal artery stenosis >70%	1	12	1 / 1,424 (0.07%)	0 / 1,029 (0%)	1.50, 0.06-36.97, p=0.80
Renal artery re-intervention	0	10	0 / 1,377 (0%)	0 / 1,040 (0%)	N.A.
Hypertensive crisis / emergency	5	9	14 / 1,248 (1.12%)	13 / 915 (1.42%)	0.65, 0.30-1.38, p=0.26
Stroke	4	8	4 / 1,160 (0.34%)	5 / 823 (0.60%)	0.54, 0.15-1.91, p=0.34
Hospitalization for HF	1	6	9 / 847	3 / 582	1.47, 0.39-5.50, p=0.57


			(1.06%)	(0.51%)	
All-cause death *	3	11	4 / 1,476 (0.27%)	1 / 1,070 (0.08%)	1.76, 0.34-9.20, p=0.50
Embolic event	1	9	1 / 1,270 (0.07%)	0 / 930 (0%)	1.45, 0.06-36.12, p=0.82
New-onset ESRD	0	8	0 / 1,316 (0%)	0 / 914 (0%)	N.A.

* - 1 death in RADIANCE HTN TRIO was sudden cardiac death unrelated to the RDN procedure, 1 death (unrelated to the study procedure, device or drug) in TARGET BP I and 2 death cases (details not stated) in SYMPPLICITY HTN Trial occurred within 6 months after the procedure,

Data are frequencies (%) and odds ratios (95% confidence intervals).

Abbreviations: ESRD, end-stage renal disease; HF, heart failure; NA, not applicable; RDN, renal denervation.

Ambulatory systolic blood pressure change



Ambulatory diastolic blood pressure change





Figure 1. Comparison of effects of renal denervation vs sham procedure on ambulatory systolic (top forest plot) and diastolic (bottom forest plot) blood pressure

Office systolic blood pressure change



Office diastolic blood pressure change





Figure 2. Comparison of effects of renal denervation vs sham procedure on office systolic (top forest plot) and diastolic (bottom forest plot) blood pressure

Daytime systolic blood pressure change



Daytime diastolic blood pressure change





Figure 3. Comparison of effects of renal denervation vs sham procedure on daytime systolic (top forest plot) and diastolic (bottom forest plot) blood pressure

Nighttime systolic blood pressure change

Study or Subgroup	RDN			Sham			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
SYMPPLICITY HTN-3	-5.6	19.4	337	-2.4	18.5	166	14.0%	-3.20 [-6.69, 0.29]	2014
RADIANCE-HTN SOLO	-4.8	11.7	74	-3.1	11.5	72	12.7%	-1.70 [-5.46, 2.06]	2018
RADIANCE-HTN TRIO	-8.1	15.7	69	-4.8	20.1	63	5.8%	-3.30 [-9.49, 2.89]	2021
RADIANCE II	-6.6	12.8	144	-1.3	11.3	72	14.8%	-5.30 [-8.64, -1.96]	2023
SPYRAL HTN-ON Extension	-6.7	12.7	194	-3	12.6	118	17.6%	-3.70 [-6.59, -0.81]	2023
Iberis-HTN	-13.1	13.9	107	-3.7	16.7	110	11.3%	-9.40 [-13.48, -5.32]	2023
Netrod RDN	-8.2	16.9	137	-1.3	16.2	66	8.8%	-6.90 [-11.73, -2.07]	2023
TARGET BP I	-9.3	14.8	148	-6	14.4	153	15.0%	-3.30 [-6.60, 0.00]	2024
Total (95% CI)			1210			820	100.0%	-4.46 [-6.07, -2.84]	

Heterogeneity: Tau² = 1.71; Chi² = 10.27, df = 7 (P = 0.17); I² = 32%
 Test for overall effect: Z = 5.39 (P < 0.00001)



Nighttime diastolic blood pressure change

Study or Subgroup	RDN			Sham			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
SYMPPLICITY HTN-3	-3.3	11.6	337	-1.5	11.2	166	18.2%	-1.80 [-3.91, 0.31]	2014
RADIANCE-HTN SOLO	-3.3	8.5	74	-2.7	7.3	72	14.0%	-0.60 [-3.17, 1.97]	2018
RADIANCE-HTN TRIO	-5.1	10	69	-3	13.3	63	6.8%	-2.10 [-6.14, 1.94]	2021
Iberis-HTN	-7.3	10.2	107	-2.9	12.6	110	10.8%	-4.40 [-7.45, -1.35]	2023
Netrod RDN	-4.2	10.8	137	-0.3	8.6	66	12.6%	-3.90 [-6.65, -1.15]	2023
RADIANCE II	-4.7	8.2	144	-0.5	6.7	72	18.9%	-4.20 [-6.25, -2.15]	2023
SPYRAL HTN-ON Extension	-4.3	8.5	194	-2.8	9.3	118	18.7%	-1.50 [-3.56, 0.56]	2023
Total (95% CI)			1062			667	100.0%	-2.60 [-3.73, -1.46]	

Heterogeneity: Tau² = 0.70; Chi² = 8.58, df = 6 (P = 0.20); I² = 30%
 Test for overall effect: Z = 4.47 (P < 0.00001)





Figure 4. Comparison of effects of renal denervation vs sham procedure on nighttime systolic (top forest plot) and diastolic (bottom forest plot) blood pressure


Efficacy and safety of catheter-based RDN vs sham in hypertension

2,478 patients with hypertension
10 high-quality, randomized, sham-controlled trials



- a) Resistant hypertension
- b) Hypertension on medication
- c) Hypertension off medication

Efficacy outcomes



Safety outcomes

